RxDoctor Payments Data

Sumodh Kalathil, MD

Gastroenterology · Greenville, SCNPI 1750318416

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.9% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 48.5% of the total.

$5,179in general payments, 2019–2025

Across 229 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$427
  • Takeda Pharmaceuticals U.S.A., Inc.$292
  • Gilead$260
  • Pfizer$191
  • Covidien LP$180
  • plus $1K from 23 others
$289,373in research payments, 2019–2025

Across 112 payments — averaging $2583.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Intercept Pharmaceuticals, Inc.$168K
  • Intercept Pharma Europe Ltd.$51K
  • Eli Lilly$33K
  • Regeneron$30K
  • Gilead$7K
  • Boehringer Ingelheim International GmbH$702

What the payments were for

  • Food & beverage$4,91595%
  • Education$2655%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,179 in reported general payments places this provider in the 65th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$90,704
Medicare patients
391
Services billed
731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$88,274
Mesalamine15$6,783
Dexlansoprazole DrDexlansoprazole11$3,280
Ursodiol23$2,846
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl83$1,319
Omeprazole93$1,208
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl34$532
Pantoprazole Sodium45$475
Sucralfate12$209
Famotidine16$149
Propranolol Hcl11$138
Prednisone17$11

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →